Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483353 | 0.92 | REN (0.84) | REN | |
| Ditekiren SCHEMBL122368 | 0.92 | REN (1.00) | REN | |
| SCHEMBL14008234 | 0.74 | REN (0.49) | REN | |
| SCHEMBL7351443 | 0.72 | REN (0.64) | REN | |
| SCHEMBL10522082 | 0.71 | CMA1 (0.53) | REN | |
| SCHEMBL9822410 | 0.71 | REN (0.52) | REN | |
| SCHEMBL11110012 | 0.71 | REN (0.68) | REN | |
| SCHEMBL10772344 | 0.70 | REN (0.54) | REN | |
| SCHEMBL7328163 | 0.69 | REN (0.59) | REN | |
| SCHEMBL9755311 | 0.69 | REN (0.67) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137774-A1 | Hepatitis B Virus Receptor OATP and Use Thereof | SHANGHAI HEP PHARMACEUTICAL CO LTD (CN) | 2026-05-21 | — | — | US | disclosed |
| EP-4556017-A1 | HEPATITIS B VIRUS RECEPTOR OATP AND USE THEREOF | Shanghai Hep Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-119497624-A | Hepatitis B virus receptor OATP and application thereof | 上海贺普药业股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024012423-A1 | HEPATITIS B VIRUS RECEPTOR OATP AND USE THEREOF | 上海贺普药业股份有限公司 | 2024-01-18 | — | — | WO | disclosed |
| CN-117222644-A | 2- ((4- ((S) -2- (4-chloro-2-fluorophenyl) -2-methylbenzo [ d ] [1,3] dioxol-4-yl) piperidin-1-yl) methyl) -1- (((S) -oxetan-2-yl) methyl) -1H-imidazole derivatives as GLP1 receptor activators for the treatment of obesity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137774-A1 | Hepatitis B Virus Receptor OATP and Use Thereof | HAVCR2, SLC10A1, FABP1 | REN 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.